Compare Salesforce Inc (CRM) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Gilead Sciences, Inc. — how do they compare? Salesforce Inc trades at $227.96 (market cap $187.48B), while Gilead Sciences, Inc. trades at $150.15 (market cap $182.40B). The key difference: Salesforce Inc and Gilead Sciences, Inc. are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Gilead Sciences, Inc. for 111 Days on average.
| CRM | GILD | |
|---|---|---|
Market Cap | $187.48B | $182.40B |
Volume | 6,155,822 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $266.23 | $155.80 |
52-Week Low | $150.12 | $116.74 |
Typical Hold Time | 89 Days | 111 Days |
Enterprise Value | $217.82B | $205.46B |
Dividend Yield | 0.77% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected) and robust profitability (77.28% gross margin, 21.99% net margin). Technical indicators signal bearish momentum with resistance at $227 and support at $222. Recent news highlights AI-driven volatility but also underscores Salesforce's positioning as an Agentic AI beneficiary.
Outlook: Salesforce's discounted valuation (P/E 20.86 vs. historical averages) and AI monetization growth (Agentforce ARR up 200% YoY) present a buying opportunity, though near-term risks include sector-wide pressure and macroeconomic uncertainty. Analyst consensus remains strongly bullish with a $271.91 price target, suggesting ~21% upside.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
